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Chronic Hepatitis C (HCV) infection is an important cause of morbidity and mortality in patients with end-stage renal disease.
Renal transplantation confers a survival advantage in HCV-infected patients. Renal transplant candidates with serologic evidence
of HCV infection should undergo a liver biopsy to assess for ﬁbrosis and cirrhosis. Patients with Metavir ﬁbrosis score ≤3
and compensated cirrhosis should be evaluated for interferon-based therapy. Achievement of sustained virological response
(SVR) may reduce the risks for both posttransplantation hepatic and extrahepatic complications such as de novo or recurrent
glomerulonephritis associated with HCV. Patients who cannot achieve SVR and have no live kidney donor may be considered for
HCV-positive kidneys. Interferon should be avoided after kidney transplant except for treatment of life-threatening liver injury,
such as ﬁbrosing cholestatic hepatitis. Early detection, prevention, and treatment of complications due to chronic HCV infection
may improve the outcomes of kidney transplant recipients with chronic HCV infection.
1.Introduction
Hepatitis C (HCV) infection remains highly prevalent in
patientswithend-stagerenaldisease (ESRD).Theprevalence
of HCV in dialysis patients varies among diﬀerent parts
of the world with up to 80% in developing countries
[1] and 1.8% [2] and 40% in developed countries [1].
Universal precautions at hemodialysis centers as well as the
introduction of screening of blood donors have led to a
noticeable decrease in HCV infection in this population;
however, nosocomial spread of HCV within dialysis units
does continue to occur [3, 4]. In the United States, the rate
of HCV infection in hemodialysis patients has declined from
10.4% in 1995 to 7.8% in 2002 [5], compared to the 1.8%
prevalence observed in the general population [6].
Renal transplantation confers signiﬁcant survival advan-
tage in HCV-infected patients with end-stage renal disease
[1, 2]. However, HCV-positive kidney transplant recipients
experienced lower long-term graft and patient survival
compared to their HCV-negative counterparts [7–9]. A
meta-analysis of 8 observational studies of 6365 kidney
transplant recipientsshowed thatpatientswithpositiveHCV
antibodies had a higher rate of death and graft failure after
kidney transplantation (relative risk 1.79 and 1.56, resp.)
[10]. Hepatocellular carcinoma and liver cirrhosis were the
more frequentcausesof deathinHCV-positive patients[10].
Indeed, liver failure has been reported as a cause of death in
8%to28%oflong-termkidneytransplant survivors[11–13].
HCV is also associated with extrahepatic complications:
de novo or recurrent glomerulopathy [9], cryoglobuline-
mic vasculitis, chronic allograft nephropathy [14], post-
transplant diabetes mellitus, and sepsis, all of which account
for the reduced graft and patient survival [1]. Analysis of the
renal transplant cohort of the Australian and New Zealand
Dialysis and Transplant Registry in which 140 of 7572
patients(1.8%)wereHCV-positiveshoweddecreasedpatient
s u r v i v a li nt h eH C V - p o s i t i v ev e r s u sH C V - n e g a t i v ek i d n e y
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at 5 and 10 years, respectively [2]. The higher rate of death
in HCV-positive patients was due to cardiovascular disease
(hazard ratio (HR)2.74),malignancy (HR2.52),and hepatic
failure (HR 22.1). HCV-positive patients also had a higher
risk of graft loss, the most frequent causes of which were
glomerulonephritis,chronicrenalallograftnephropathy,and
death [2].
The management of kidney transplant recipients with
chronic HCV infection is complex. In this paper, we will
discuss the following:
(1) the evaluation of HCV in renal transplant candidates
and the available treatment options of HCV before
transplantation,
(2) the use of HCV-positive donor kidneys,
(3) the monitoring of liver disease progression after
transplantation,
(4) the management of HCV-associated extrahepatic
complications.
2.Evaluationof HCV-PositiveRenal
TransplantCandidates
All patients undergoing a renal transplant evaluation should
be screened for chronic HCV infection with a third gen-
eration anti-HCV enzyme-linked immunoassay. If this is
positive, conﬁrmation of active infection with a highly
sensitive quantitative assay for HCV RNA should be per-
formed. The rate of false negative results is quite low with a
third generation immunoassay in patients on hemodialysis
[15]. The risk of reactivation in patients who are HCV
antibody positive but HCV RNA negative is extremely rare,
even in situations of considerable immunosuppression. A
recent study conﬁrmed that patients with previous HCV
infection demonstrated by the presence of HCV antibody,
but persistently negative HCV RNA, continued to have no
evidence of hepatitis C viral replication in liver biopsies
and peripheral blood mononuclear cells up to 16 years after
kidney transplantation, despite the use of chronic immuno-
suppressionandoftenaggressiveinductionimmunosuppres-
sion, including antithymocyte globulin and IL-2 receptor
blockers[16].
It is generally accepted that HCV-positive patients being
evaluated for kidney transplantation should undergo a liver
biopsy to assess for the presence of advanced ﬁbrosis, unless
there is clear radiological or clinical evidence of portal
hypertension or cirrhosis. Cirrhosis has a prevalence of
approximately 10% in ESRD patients with chronic HCV
infection [17]. The presence of cirrhosis is usually consid-
ered to be a contraindication to renal transplantation, but
these patients can be considered for combined liver-kidney
transplantation, if there is evidence of decompensated liver
disease and portal hypertension. Patients with unremarkable
histology can undergo kidney transplantation alone. Patient
with Metavir ﬁbrosis score ≤3 and compensated cirrhosis
should be considered for interferon- (IFN-) based treatment
[18, 19], taking into consideration the HCV genotype, side
eﬀect proﬁles of the therapy, and the patient’s willingness
to comply with the regimens. Liver function tests correlate
poorly with histological severity in HCV-positive patients
receiving hemodialysis [20, 21]. Furthermore, patients with
ESRD have been found to have less histological activity on
liver biopsy, characterized by less inﬂammation and less
ﬁbrosis compared with controls [21, 22].
3.LiverBiopsy inHemodialysisPatients
Percutaneouslive biopsy is a safe procedure when performed
by experienced operators; however, patients with cirrhosis
and other bleeding diatheses can often have an increased
risk ofhemorrhage requiring hospitalization. Aretrospective
analysis compared the safety of percutaneous liver biopsy
in chronic HCV patients with and without ESRD [22].
Only 1 patient (1.3%) with ESRD developed a moderate
complication,comparedwitha2.1%complicationrateinthe
control group, with 3 of them having a severe complication.
In hemodialysis patients with a suitable coagulation proﬁle
(INR < 1.5, Platelet count >70,000, and absence of blood
thinners, including aspirin and ibuprofen products), there
are currently no data to suggest that percutaneous liver
biopsy should be contraindicated. However, patients with
ESRD often have coagulation defects and are thought to
have an overall increased risk of procedure-related bleeding
[23, 24].
Transjugular liver biopsy (TJLB) is an alternate means
of obtaining liver tissue in patients with coagulopathy and
suspected bleeding risk. The results of 46 hemodialysis
patients with chronic liver disease undergoing TJLB were
compared to 32 hemodialysis patients who had previously
had a percutaneous liver biopsy at the same institution [25].
Both techniques yielded adequate specimens for histological
diagnosis in all patients. No major complications were
observed in the patients who underwent TJLB compared
with a 12% bleeding complication rate in the percutaneous
liver biopsy group. Both the INR and platelet count were
well above the appropriate threshold for the procedure in
both groups. Although this is a much higher complication
rate than that seen in previous studies, it certainly raises
the question about whether or not TJLB should be the
method of choice for obtaining liver tissue in patients on
hemodialysis. The TJLB does have the additional beneﬁt
of obtaining portal pressure measurements, which may be
useful clinically. Moreover, the transjugular approach should
be used in patients on peritoneal dialysis.
4.Noninvasive Markersof Fibrosis
Non-invasive markers of ﬁbrosis provide a safe method of
determining the presence of advanced liver disease, although
predictive values vary and many of the assays have not been
validated in ESRD patients. The FibroTest (BioPredictive,
France), which consists of α2-macroglobulin, haptoglobin,
γ-glutamyl transpeptidase, total bilirubin, and apolipopro-
tein A1 levels, has been evaluated in both hemodialysis
patients and kidney transplant recipients with HCV infec-
tion. In 50 ESRD patients, it was found to have a positive
predictive value (PPV) of 75% to detect Metavir F2-F4 forInternational Journal of Nephrology 3
scores greater than 0.60, with a negative predictive value
(NPV) of 71% for scores lower than 0.20 [26]. Recent
data yielded contradictory results: the authors suggested
that the variability of the components of the FibroTest
in hemodialysis patients may explain the diﬀerence [27].
For example, lipoprotein metabolism is altered in uremic
patients. The literature suggests that a component of uremic
serum inhibits hepatic apolipoprotein A-1 synthesis [28].
α2-macroglobulin is an acute-phase reactant and in addition
to its association with liver ﬁbrosis, can also be produced
at sites of inﬂammation, which can be induced during
t h ed i a l y s i sp r o c e d u r e[ 29]. The FibroTest is not currently
recommended as an alternative to liver biopsy in renal
transplant candidates.
An aspartate transaminase (AST) to platelet ratio index
(APRI) <0.40 accurately identiﬁed patients on hemodialysis
with Ishak Fibrosis stage 0 or 1 in 93% of the cases (NPV =
93%), and all subjects who were misclassiﬁed had a ﬁbrosis
score of F2. An APRI cutoﬀ >0.95 was able to conﬁrm
signiﬁcant ﬁbrosis with a PPV of 66%. If biopsy indication
was restricted to APRI scores in the intermediate range
(>0.40 and <0.95), 52% of liver biopsies could have been
correctly avoided [30]. These results were conﬁrmed in a
recent prospective analysis that found the APRI to be an
accurate and reproducible method of measuring signiﬁcant
ﬁbrosis in hemodialysis patients with chronic HCV [31].
This method of measuring ﬁbrosis needsto be fully validated
but could potentially be useful in limiting the number of
liver biopsies performed in those being evaluated for kidney
transplantation.
5.HCVTreatmentinRenal
TransplantCandidates
Chronic HCV infection leads to signiﬁcant long-term mor-
bidity and mortality in kidney transplant recipients. The
treatment of HCV with interferon (IFN) after transplan-
tation should be avoided because of an increased risk of
rejection [1, 3, 18].
Preemptive HCV treatment of kidney transplant candi-
dates has been shown to improve patient and graft survival
[32–34]. Achievement of sustained virological response
(SVR) with treatment of HCV not only can prevent pro-
gression of liver disease but also reduce the development
of posttransplant complications, including HCV-associated
nephropathy [35] and new onset diabetes mellitus [36]. SVR
is deﬁned as the absence of blood HCV RNA six months
after antiviral treatment. Several studies have conﬁrmed
that patients who achieve an SVR pretransplant while on
hemodialysis with either standard IFN or pegylated-IFN
(PEG-IFN) do not experience reactivation of the virus after
kidney transplantation, despite high doses of immunosup-
pression [37, 38]. Cruzado et al. reported that in 15 HCV+
kidney transplant recipients, 10 (67%) of who received IFN
pre-transplant, only 1 patient who did not receive treatment
and was viremic at the time of transplantation developed
de novo glomerulonephritis [35]. In 63 patients who did
not receive IFN, 28.7% had negative HCV-PCR. Twelve of
these 63 patients developed de novo glomerulonephritis.
All 12 patients were viremic at time of transplantation
[35]. These data provide the impetus to treat HCV-infected
individuals while awaiting kidney transplantation.
5.1. Interferon and Ribavirin. Combined PEG-IFN and
ribavirin is considered the standard treatment for HCV
infection in patients with normal renal function. Ribavirin
is primarily eliminated by the kidney. In patients with
glomerular ﬁltration rate less than 30mL/min, the area
under the blood concentration-time curve is three times
higher than that in patients with normal renal function
[39]. The main signiﬁcant adverse eﬀect is hemolytic ane-
mia [39]. Although advanced kidney disease has generally
been considered a contraindication to ribavirin use, some
clinicians prescribe ribavirin in signiﬁcantly reduced doses
to hemodialysis patients (e.g., 200mg three times weekly)
[39, 40]. If this approach is taken, patients should be closely
monitored for anemia and other adverse events. High doses
ofrecombinant erythropoietinare usuallyneededtoalleviate
the anemia [39, 40].
A recent meta-analysis of chronic HCV patients on
hemodialysis treated with IFN reported a treatment discon-
tinuation rate of 26% due to adverse events, signiﬁcantly
higher than that reported for IFN-treated nonhemodialysis
patients (95% conﬁdence interval (CI), 9 to 14) [41]. This
was accompanied, however, by a 41% SVR rate, much
greater than the 10 to 20% SVR rates observed in previously
published studies of nonhemodialysis patients treated with
IFN monotherapy [42, 43]. This is thought to be due to an
increased half-life of IFN in hemodialysis patients, resulting
in greater plasma IFN levels, increased eﬃcacy and adverse
events.
PEG-IFN also has been studied in patients with ESRD.
SVR rates between 45% and 75% have been observed with
PEG-IFN monotherapy in hemodialysis patients [44–46].
Treatment discontinuation rates due to adverse events range
from 0 to 33%, with anemia being the most common side
eﬀect.Itisdiﬃculttodraw conclusionsonrecommendations
as the results are quite varied. Treatment eﬃcacy and
tolerability of PEG-IFN in patients with ESRD need to be
conﬁrmed in a larger prospective clinical trial. Alavian and
Tabatabaei performed a meta-analysis of 21 studies on IFN
(491 patients) and 12 studies on PEG-IFN (279 patients)
to assess the eﬀectiveness of IFN compared to PEG-IFN
monotherapy [47]. The pooled SVR for IFN and PEG-IFN
was 39.1% (95% CI, 32.1 to 46.1) and 39.3% (95% CI,
26.5 to 52.1), respectively. The pooled dropout rates were
22.6% (95% CI, 10.4 to 34.8) and 29.7% (95% CI, 21.7 to
37.7), respectively [47]. Hence, whether PEG-IFN confers
additional beneﬁts in terms of SVR and adverse events is
unclear.
There are limited studies of the use of combined IFN or
PEG-IFN with ribavirin in patients with advanced kidney
disease. Fabrizi et al. conducted a meta-analysis of 10
clinical trials (only one of which was a controlled study)
involving 151 patients, 97.4% of who were hemodialysis
patients [48]. The summary estimates for SVR and drop-
out rate were 56% (95% CI, 28 to 84) and 25% (95% CI,
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were anemia (26%) and heart failure (9%) [48]. However,
there was signiﬁcant heterogeneity in SVR and drop-out
rates among the studies. Prospective controlled trials are
neededtoassesstheeﬃcacyandtolerabilityofcombinedIFN
or PEG-IFN with ribavirin compared to IFN or PEG-IFN
monotherapy.
It is well known that HCV genotype can signiﬁcantly
impact the response rate to IFN and ribavirin. Hence, it
is routine to obtain genotype testing prior to initiation
of treatment. Studies have shown that the prevalence of
HCV genotypes in patients with ESRD is quite similar
to that in the general population, with the majority of
patients being infected with either genotype 1a or 1b [49].
In addition, the HCV genotype does not seem to have an
impact on survival in kidney transplant recipients [49].
There are virtually no dataon comparing treatment response
of the various genotypes in patients on hemodialysis, but
small studies do suggest that genotype 1 patients are able
to achieve an SVR anywhere from 28% to 75% of the
time with a 48-week course of PEG-IFN monotherapy
[50–52].
For HCV-infected patients with chronic kidney disease
on maintenance hemodialysis, the 2008 KDIGO guidelines
recommend monotherapy with standard interferon that is
dose adjusted for a glomerular ﬁltration rate less than
15mL/min [19]. Strong data are not available to make
dosing and treatment duration recommendations. However,
a regimen of three million units of IFN α-2b given subcu-
taneously three times per week or PEG-IFN α-2a 135mcg
weekly for 6 to 12 months appears to be safe and eﬀective in
inducing an SVR [39]. Ribavirin can be initiated at 200mg
daily or 200mg three times weekly with close monitoring of
anemia and adverse events in patients who have no virologic
response to IFN or PEG-IFN [39, 40, 48].
5.2. Protease Inhibitors. The incomplete eﬀectiveness of
treatment with PEG-IFN and ribavirin has prompted the
development of selective inhibitors of HCV. The NS3/4A
proteaseinhibitors, which speciﬁcally targetviral replication,
have been shown to have potent antiviral activity in HCV
repliconassays.Ininitialclinicalstudies,theNS3/4Aprotease
inhibitors have been well tolerated with substantial antiviral
activity [53]. Results of two phase II studies—PROVE 1
and PROVE 2—have shown safety and eﬃcacy of the triple
regimen of IFN α-2a, ribavirin, and telaprevir in patients
with untreated chronic HCV (genotype 1) [54, 55]. PROVE-
2 also included a telaprevir and IFN α (without ribavirin)
arm that was treated for 12 weeks. Patients who received
telaprevir and PEG-IFN without ribavirin were less likely to
achieve HCV RNA suppression and more likely to relapse
than were those who received the triple combination.
There are no data on the safety and eﬃcacy of the HCV
protease inhibitors, telaprevir and boceprevir, in patients
with ESRD. The HIV protease inhibitors, however, are
hepatically cleared, and appear to be safe in patients with
chronic renal failure, as well as for those on hemodialysis
[56,57].Additionalpharmacokineticstudiesneedtobedone
in order to deﬁne dosing recommendations in patients on
hemodialysis.
6.UseofHCVAntibody-PositiveDonorKidneys
While it is well accepted that kidneys from HCV-positive
donors should not be transplanted into HCV-negative
recipients, the use of kidneys from HCV-infected donors for
transplant in HCV-positive recipients has been controversial
[1,18, 19]. The use of HCV-positive kidneysmay shorten the
waiting times for ESRD patients with chronic HCV infection
and may increase the availability of HCV-negative kidneys
to HCV-negative recipients. Several single center studies had
shown similar short-term graft and patient survival with no
increase in acute rejection compared to those who received
HCV-negative kidneys [58].
A recent analysis of the UNOS database from 1995
to 2009 showed that HCV-positive kidneys were 2.6 times
more likely to be discarded [59]. Twenty-nine percent of
6830 patients received HCV-positive kidneys. On average,
the waiting time decreased from 856 to 469 days. HCV-
positivekidneyrecipientshad a1.29timesriskofdeath(95%
CI 1.15–1.45, P<. 001) [59]. However, this hazard ratio
only translated into a diﬀerence of 1% in 1-year survival
between HCV-negative and HCV-positive kidney recipients
(94% versus 93%) and a 2% diﬀerence in 3 year survival
(85%versus83%).Interestingly,non-African Americanshad
a higher death risk when receiving an HCV-positive kidney
(hazard ratio 1.6, 95% CI 1.35–1.90, P<. 01) [59]. African
Americans, patients older than 60, diabetics and highly
sensitized patients did not have signiﬁcantly increased risk
of death. Similarly, recipients of kidneys from HCV-positive
donors had a 1.18 times risk of graft loss, compared to
those receiving HCV-negative kidneys[59]. Patients younger
than 60, those without diabetes, those with panel reactive
antibodies <80%, and those with BMI < 35kg/m2 were
associated with an increased hazard of graft loss.
The early experience in 2 transplant centers in Spain
showed transmission of HCV RNA in HCV antibody-
positive recipients who were negative for HCV RNA [60].
The policy was then changed to only transplant HCV-
positive kidneys to HCV-positive recipients with viremia.
An update of the long-term experience from Spain using
HCV-positive kidney donor was reported [60]. There was
no diﬀerence in the 5- and 10-year patient survival between
162 recipients of HCV-positive kidneys versus 306 recipients
of HCV-negative kidneys: 84.8% and 72.7% versus 86.6%
and 76.5%, respectively, P = .250 [60]. Three deaths
in HCV-positive kidney recipients and 2 in HCV-negative
kidney recipients were related to liver disease. There was no
statistically signiﬁcant diﬀerencein the 5- and 10-yeardeath-
censored graft survival, 69% and 47% in the HCV-positive
kidney recipients versus 72.7 % and 58.5% in the HCV-
negative kidney recipients, P = .05 [60]. The incidence of
decompensated liver disease was also not diﬀerent between
the 2 groups: 10.3% versus 6.2%. Donor HCV serology was
notfoundtobea riskfactor fordeath,graftfailureandsevere
liver disease [60]. Hence, transplantation of kidney from
an HCV-positive donor to an HCV-positive recipient with
detectable HCV RNA appeared to be safe with satisfactory
outcome [19]. Nucleic acid test should be done in HCV-
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The eﬀect of superinfection with a diﬀerent HCV
geno-type when an HCV-positive kidney is transplanted
into an HCV-positive recipient remains to be studied
[18]. Severe HCV infection with genotype 1 has been
reported in a 3-time kidney transplant recipient who was
chronically infected with HCV genotype 2a [61]. Hence,
the beneﬁts and risks of receiving HCV-positive donor
kidneysshould be discussed and explained with thepotential
renal transplant candidate so that a well informed deci-
sion can be made [19]. Of course, the option of living
donor kidney transplantation should always be encour-
aged.
7.HCVand Immunosuppression
The impact of chronic immunosuppression on the course
of HCV infection in renal transplant recipients is not well
deﬁned. Corticosteroids at high doses have been shown to
increase HCVviremia, probablybyupregulationofcellentry
factorssuchasoccludinandscavengerreceptorclassBtype1,
and result in HCV dissemination [62]. The eﬀect of low
maintenance doses is unclear.
The safety and eﬃcacy of Campath-1 induction and
a steroid-free maintenance regimen with tacrolimus and
mycophenolate were evaluated in 24 HCV-positive kidney
transplant recipients [63]. During a mean followup of 15
months, there were 3 graft loss and 3 deaths (unrelated to
liver disease), with 79% allograft survival and 83% patient
survival [63]. Abnormal liver function tests were found in
3 patients, one due to fatty liver, one had been treated with
steroidsforacuterejection, and onetreatedwith leﬂunomide
forBKvirus.NoexacerbationofHCVinfectionwasreported
[63].
The eﬃcacy and safety of a rapid steroid tapering regi-
men under antilymphocyte antibody induction was studied
in HCV-positive kidney transplant recipients [64]. Twelve
patients received induction treatment with antilymphocyte
antibody followed by rapid steroid withdrawal over 6 days
andmaintainedoncalcineurininhibitorandmycophenolate.
Seventeen patients received standard steroid taper. On
followup (median followup of 12 months in the rapid
steroid taper group and 21 months in the historical control
group), there was no diﬀerence in patient survival 92%
versus 92% and graft survival 92% versus 82% between
the rapid steroid withdrawal and the standard steroid taper
groups [64]. There was also no diﬀerence in acute rejection
episodes and post-transplant liver abnormalities between
the 2 groups.
Cyclosporine has been shown to have anti-HCV activity
in cultured cells [65]. However, its eﬀect on HCV clini-
cally is unclear. Whether mycophenolate is detrimental in
terms of graft and patient survival in kidney transplant
patients with chronic HCV infection is unclear [19]. In
a recent registry data analysis, the use of mycophenolate
as part of maintenance immunosuppression was associated
with better patient survival [66]. This beneﬁcial eﬀect was
not demonstrated with cyclosporine, tacrolimus, sirolimus,
azathioprine and steroids. Interestingly, in the same study,
the use of antilymphocyte antibody induction was not
associated with lower patient survival [66]. In a small study
of 7 HCV-positive kidney transplant recipients treated with
rituximabfordenovocryoglobulinemicglomerulonephritis,
there were no signiﬁcant changes in aminotransferase,
bilirubin, and viral load 6 months post-rituximab therapy
[67].
Though most immunosuppressive agents increase viral
replication, the implication is unclear. Selection of speciﬁc
immunosuppressive regimens should be individualized and
balanced between the potential eﬀect on HCV-associated
hepatic and extra-hepatic complications [19]. Prospective
controlled studies are needed to assess the impact of various
immunosuppressive regimens on chronic HCV infection in
kidney transplant recipients.
8.EvaluatingHCVafterKidneyTransplantation
The natural history of HCV-related liver disease in kidney
transplant recipients is controversial; however, there are
some data to suggest that progression rate to cirrhosis
m a yb es l o w e ri nH C V - p o s i t i v er e n a lt r a n s p l a n tr e c i p i -
ents compared to HCV-positive controls without kidney
disease [68]. One analysis of 51 HCV-RNA-positive kid-
ney transplant patients who underwent a mean of three
consecutive liver biopsies after transplantation every 3-4
years found that liver ﬁbrosis progressed at a rate of
0.09 ± 0.03 Metavir units/year [69]. Only 3 of the 51
patients developed cirrhosis during long-term followup.
Nonetheless, liver biopsy remains the gold standard to assess
the progression of HCV-related liver disease after kidney
transplantation. The risks of percutaneous liver biopsy as
previously discussed and the presence ofsampling errorhave
led to the evaluation of both the laboratory and radiological
methods of assessing liver ﬁbrosis. None of these, however,
have been validated in the postkidney transplant popula-
tion.
Ultrasoundelastography,known commerciallyasFibros-
can, has been evaluated as a noninvasive method to evaluate
liver ﬁbrosis in kidney transplant patients. It is a radiologic
technique that uses a modiﬁed ultrasound probe to measure
the velocity of a shear wave created by a vibratory source
[70].Estimatesofstiﬀnessoftheliverbyultrasound correlate
withﬁbrosisstage[71].AllpatientswithlowFibroscanscores
(n = 13;5.2kPa)exhibitedthelowest stageofliverﬁbrosisby
biopsy accompanied by normal liver function. In contrast,
patients with high Fibroscan scores (n = 6; 11kPa) showed
a severe form of liver ﬁbrosis with clinical evidence of portal
hypertension [72]. Fibroscan appears to be a promising test
in following ﬁbrosis progression in kidney transplant recip-
ients, but it has not yet been approved for use in the United
States.
TheKDIGOguidelinesrecommendedmonthlymeasure-
ment of liver function test in the ﬁrst 6 months and then
every 3 months thereafter [19]. Patients with worsening
trend in liver enzymes should be referred for Hepatology
evaluation. In patients with cirrhosis on liver biopsy, annual
liver ultrasound and alpha-fetoprotein measurement should
be considered [19].6 International Journal of Nephrology
9.HCVand De Novo and Recurrent
GlomerularDiseases
Chronic infection with HCV has been linked to the patho-
genesis of glomerular diseases, both in native as well as
transplanted kidneys. There is an increased incidence of
proteinuria among HCV-positive renal transplant patients
compared to HCV-negative patients [73].
9.1. HCV-Associated Glomerular Lesions after Transplanta-
tion. Membranoproliferative glomerulonephritis (MPGN),
with orwithout cryoglobulinemia is the most common renal
lesion associated with chronic HCV infection in the renal
transplant recipients [74, 75]. The second most important
de novo glomerular disease frequently seen in such cases
is membranous glomerulonephritis (MGN) [75–77]. The
pathogenesis of these lesions is similar to what occurs
in native kidneys—deposition of HCV-protein containing
immune-complexes in the glomeruli, which occurs despite
immunosuppressive therapy. A possible explanation of this
phenomenon is that immunosuppression increases HCV
viral load and reduces immunoglobulin synthesis, leading
to an imbalance of antigen-antibody complex status, which
interferes with their clearance and leads to their deposition
in the allograft [78]. Kamar et al. have suggested that HCV-
positive patients who developed de novo glomerulonephritis
have a higher immune response and/or particular cytokine
productionratherthan adirect eﬀectof HCVonkidney cells
[79]. In addition to MPGN and MGN, Baid et al. described
the association of HCV infection with the development of
de novo thrombotic microangiopathy in the renal allograft,
especially in patients with pretransplant anticardiolipin
antibodies [80]. Cosio et al. also showed a high incidence
of acute transplant glomerulopathy in HCV-positive kidney
transplants [81].
9.2.Posttransplant ManagementofHCV-Positive Renal Trans-
plants. Asthere isincreased risk ofdevelopmentofglomeru-
lopathy and graft loss in HCV-positive patients, close
monitoring for thedevelopmentofproteinuria isrequired. It
is recommended that a baseline urinalysis and urine protein-
to-creatinine ratio should be obtained within the ﬁrst two
weeks after transplant or once the renal function is stable
[19]. Screening for proteinuria should be done every 3–6
months for the ﬁrst year and every 6 months thereafter. If
a patient develops signiﬁcant proteinuria (deﬁned as urine
protein-to-creatinine ratio of >1.0 or 24-hour urine protein
>1.0g on two or more occasions) or microscopic hematuria
(without any other identiﬁed cause), a renal allograft biopsy
shouldbeperformed[19].Thekidneybiopsyshouldbestud-
ied with light microscopy, immunoﬂuorescence techniques
and electron microscopy. Diﬀerentiation of MPGN from
chronic transplant glomerulopathy should be done as this
may inﬂuence subsequent therapy. Immunological and sero-
logic studies, especially cryoglobulin and complement levels,
may be useful in the diagnosis of cryoglobulinemic MPGN.
Electron microscopy can help to distinguish these entities,
especially inpatientswithnoncryoglobulinemicMPGN. The
presence of large subendothelial electron-dense deposits is
diagnostic of MPGN, whereas the mere presence of thick-
ening and duplication of glomerular basement membrane
favors the diagnosis of chronic transplant glomerulopathy.
Pre-transplant use of IFN-based therapies for treatment
of HCV infection may prevent the development of post-
transplant glomerulonephritis. In kidney transplant recipi-
ents diagnosed with HCV-associated glomerulopathy, use of
interferon-α-based therapies should be generally avoided as
use of IFN in the setting of kidney transplant is associated
with an increased risk of renal allograft rejection, including
antibody-mediated rejection [1, 19, 82]. Antiviral therapies
such as ribavirin can be used in kidney transplant recipients
with HCV-associated glomerulopathy [83]. Ribavirin helps
to reduce proteinuria, but it does not lead to viral clear-
ance. Other nonspeciﬁc antiproteinuric therapies such as
blockade of the renin-angiotensin-aldosterone system with
angiotensin-converting enzyme inhibitors and angiotensin-
receptorblockersmay alsobeused astolerated.Insuchcases,
careful monitoring of renal function, serum potassium and
hemoglobin levels is required.
In cryoglobulinemic glomerulonephritis, high-dose in-
travenouspulsesteroidsfollowedbysteroidtapercanbeused
forthetreatment ofseverenephriticornephroticproteinuria
associated with renal dysfunction. In addition, cytotoxic
drugslikecyclophosphamidehavebeen used forseverecases.
Cyclophosphamide improves renal disease by suppressing
B-lymphocyte stimulation and cryoglobulin production.
However, such therapies are associated with a high rate of
morbidity andmortality evenin immunocompetent patients
[84]. In addition, the eﬃcacy of these treatments remains
unclear. In patients with native kidney cryoglobulinemic
glomerulonephritis, plasma exchange three times a week for
2to3weekshasbeensuccessfullyused[85].Plasma exchange
aims to remove circulating cryoglobulins, inﬂammatory
mediators and toxins. However, there are no deﬁnitive data
for its use in renal transplant patients for this indication.
Regardless, plasma exchangeis extensivelyand safelyused for
other indications in this population.
Rituximab is a chimeric monoclonal antibody that binds
to the B cell surface antigen CD 20 and leads to rapid deple-
tion of B-cells in the peripheral blood. Thus, it interferes
with monoclonal IgM production, cryoglobulin synthesis
and renal deposition of immune complexes. Rituximab has
been used successfully for the treatment of cryoglobulinemia
in non-immunocompromised patients [86, 87]. Basse et al.
used rituximab in 7 renal transplant patients (5 of who were
HCV positive) with MPGN associated with mixed cryoglob-
ulinemia [88]. Use of 2–4 doses of rituximab was associated
with a sustained clearance of cryoglobulins and a signiﬁcant
reduction in proteinuria. However, 2 of these patients devel-
oped severe infections. Prospective trials to fully investigate
the role of rituximab in this population are warranted.
Novel therapies like imatinib are being studied in animal
models for the treatment of cryoglobulinemia and MPGN.
Imatinibisatyrosinekinaseinhibitor.Inmicewithcryoglob-
ulinemia and MPGN, use of imatinib led to the reduction
in cryoglobulin production and the reversal of renal and
systemic lesions [89]. Further studies in humans, speciﬁcally
in renal transplant patients, are still required.International Journal of Nephrology 7
In summary, de novo and recurrent glomerulopathies
are common in renal transplant patients with HCV infec-
tion and are associated with poorer allograft and patient
survival. These patients should be closely monitored for
the development of complications from HCV infection. A
careful evaluation to identify the cause of renal dysfunction
should be undertaken in these patients. Use of interferon
therapy should be avoided. All patients should receive
antiproteinuric therapy as tolerated and antiviral treatment
may be considered. High-dose corticosteroids and plasma
exchange may be used in acute and severe cases. Rituximab
may be tried in refractory cases.
10.HCVand New Onset Diabetes
afterTransplantation
HCV has been associated with diabetes mellitus in both pre-
and posttransplant patients. The incidence and prevalence
of new onset diabetes after transplantation (NODAT) are
variable because of the diﬀerent deﬁnitions used, the organ
transplanted, and the duration of followup [90]. A meta-
analysis of multiple clinical studies reported the incidence
of NODAT between 7.9% and 50% [36]. Bloom et al.
reported a prevalence of 39.4% in HCV-positive kidney
transplant recipients compared to 9.8% of HCV-negative
patients, P<. 0005 [91]. Kasiske et al. found that NODAT
increased the risks of both graft failure (HR 1.63, P<. 0001)
and death (HR 1.87, P<. 0001) [92]. The mechanisms for
HCV-associated diabetes mellitus are multiple and include
increased insulin resistance, impaired insulin sensitivity
[93], reduced hepatic glucose uptake and glycogenesis, and
direct viral cytopathic eﬀect on pancreatic β cells [90]. In
transplant patients other mechanisms may come into play:
obesity, older age, African American and Hispanic ethnici-
ties, metabolic syndrome, and immunosuppressive therapy,
including calcineurin inhibitors [94]a n ds t e r o i d s[ 90].
Bloom et al. reported that 57.8% of HCV-positive patients
treated with tacrolimus developed NODAT compared with
7.7%oncyclosporinetherapy (P<. 0001)[91]. Interestingly,
there was no diﬀerence in NODAT between the HCV-
negative recipientsusing tacrolimusversuscyclosporine10%
and 9.4%, respectively, P = .521 [91].
Early diagnosis and appropriate treatment of NODAT
are important. Patients diagnosed with diabetes mellitus
as deﬁned by the American Diabetic Association criteria
should be referred to the diabetologist for further evaluation
and management [19]. Steroid minimization and reduction
in tacrolimus or conversion to cyclosporine may help to
minimize the risk of NODAT. Increased physical activity,
weight loss, and treatment of the various components
of the metabolic syndrome are important aspects in the
management of NODAT. Achievement of SVR with antiviral
treatment can reduce the risk of HCV-associated NODAT.
11.Conclusion
Chronic HCV infection is an important cause of morbidity
and mortality in patients with ESRD.Kidneytransplantation
confers a survival advantage in HCV-infected patients.
Renal transplant candidates with serologic evidence of
HCV infection should undergo a liver biopsy to assess for
ﬁbrosis and cirrhosis. Patients with Metavir ﬁbrosis score
≤3 and compensated cirrhosis should be evaluated for IFN-
based therapy. Achievement of SVR may reduce the risks
for both the hepatic and extrahepatic complications such
as glomerulonephritis and NODAT associated with HCV.
PatientswhocannotachieveSVRandhavenolivedonormay
be considered for HCV-positive kidneys. Interferon should
be avoided after kidney transplant except for treatment of
life-threatening liver injury, such as ﬁbrosing cholestatic
hepatitis. Early detection, prevention, and treatment of
complicationsduetochronicHCVinfectioncanimprovethe
outcomes of HCV-positive kidney transplant recipients.
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